Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,811 total articles
ServiceNow is positioned to report another AI-accelerated quarter. With a $29B backlog, $4.6B in free cash flow and improving technical momentum, the pieces point to a Q3 beat. This is a tactical swing long: enter at market, limit risk with a $115 stop, target $150 as investors re-rate durable AI workflow monetization.
Frontline plc (FRO) looks expensive to some screens - price near a 52-week high and elevated PB - but dividend yield (7.2%), improving tanker fundamentals and bullish momentum create a compelling mid-term trade. Entry $44.43, stop $39.00, target $52.00; mid-term (45 trading days) outlook.
Meta's shares have retraced sharply from last year's peak as a major child safety trial and broader market risk-off sentiment weigh on the name. At $550 today, the company still generates robust free cash flow ($40.98B) and trades at ~20x earnings, leaving room for upside if ad demand stabilizes and litigation proves containable. This note lays out…
PayPal’s board rejected a $60.50-per-share joint offer from Stripe and Advent International. With a $52B+ market cap, strong free cash flow and a low multiple profile, PayPal is an attractive takeover target that could prompt a renewed bid above the current $61 area. This note lays out an actionable trade: enter at $61.35, target $70.00, stop $58.0…
SK hynix sits at the intersection of secular AI memory demand and a highly consolidated supply base. For disciplined traders willing to tolerate memory cyclicality, a controlled long-term long can capture significant upside if industry economics and M&A dynamics accelerate.
Himax (HIMX) is a small-cap semiconductor specialist that quietly supplies display drivers, wafer-level optics and LCoS microdisplays into automotive and AR chains. The business combines in-house manufacturing, steady cash return via dividends, and recent product ramps (OLED touch controllers, Front-lit LCoS) that justify a tactical long. We lay ou…
Teradyne is benefiting from an AI-led memory and semiconductor cycle that is pushing test volume and complexity higher. Strong Q2 results and bullish guidance justify an upgraded buy, but near-term volatility and stretched multiples argue for a dip-entry approach. Trade plan included for a mid-term swing with clear entry, stop and target.
Elanco's recent quarterly beat, new emergency-use approvals, and continued pet-care tailwinds create a practical long trade with clearly defined entry, stop and target. The company trades at roughly $12.2B market cap, generates positive free cash flow, and carries moderate leverage - a setup where execution on product launches will control the next…
UiPath has moved from growth skepticism to hitting profitability, raising guidance and showing early success with agentic AI orchestration. With a market cap near $8.2B, attractive cash flow, improving margins and heavy short positioning, the risk/reward favors a tactical long over the next 45 trading days if ARR and execution continue to validate …
Sensata Technologies is a sensor and electrical-protection specialist showing clear operational cash-generation and addressable-market tailwinds from EVs, charging infrastructure, and industrial electrification. The stock is trading below key moving averages with an attractive free-cash-flow yield versus peers; this trade targets a mid-term re-rati…
Journey Medical's Q2 narrative and commercial update show Emrosi gaining prescription traction despite reimbursement timing noise. At a $192M market cap, improving script flow, falling short interest and bullish technicals create a favorable risk/reward for a mid-term long trade. This idea includes a clear entry at $6.81, a $9.25 target and a $5.25…
LightPath Technologies is increasingly relevant to Western defense and commercial optics supply chains. The company's infrared and thermal optics wins, low leverage, and recently strengthened balance sheet set up a tactical long. We lay out an actionable swing trade with clear entry, target and stop, plus the catalysts and risks that will move the …
Alphabet looks like a classic compounding machine: dominant cash-generating core, an expanding AI moat, and a long-term buyer in Berkshire Hathaway reinforcing the narrative. The valuation and balance sheet give room for patient, structured exposure. This trade idea lays out an actionable plan with entry, stop, and target and explains why the risk/…
Genesco is showing the kind of operating resilience and cash generation that justifies upgrading the stock. Revenue growth at the Journeys division, a clean balance sheet, and low EV/EBITDA and price-to-book multiples give a favorable risk-reward. This trade plan targets a move toward the 52-week high while keeping a disciplined stop.
Rivian's early R2 sales and Q2 margin improvement give the company a clearer path to profitability. With a market cap near $22.8B, improving software and services margins, and meaningful liquidity commitments, this trade favors a long on a measured pullback. Entry at $15.00, stop at $13.50, target at $22.00 over a mid-term (45 trading days) horizon…
Blue Owl (OWL) looks set to extend a multi-week rebound. The alternative asset manager generates meaningful free cash flow, supports a high distribution yield, and has seen short interest ease — a combination that can fuel a mid-term rally. Trade plan: enter at $11.78, target $14.72, stop $10.20. Horizon: mid term (45 trading days).
Travere Therapeutics has run hard from its 52-week low, but its $6.2B market cap and $6.5B enterprise value still leave room for gains if its rare-disease franchise and pipeline continue to convert. Momentum is healthy, free cash flow is positive, and short interest plus activist/legal noise create both downside risk and upside fuel. I outline an a…
Baidu trades at $92.37 with a $37.3B market cap and oversold momentum. The planned IPO of Kunlunxin - Baidu's AI chip and model arm - could force the market to separately value Baidu's high-growth AI franchise versus its legacy search and iQiyi segments. This trade targets a mid-term re-rating on positive IPO reception, product wins, or acceleratin…
Marvell has been swept up in AI infrastructure enthusiasm. The stock is richly valued on thin margin of error: market cap near $205B, trailing P/E in the 70s and FCF yield below 1%. This trade idea proposes a tactical short to fade an overstretched move while offering clear entry, stop and target levels with a mid-term horizon.
Nu Holdings remains one of the highest-conviction growth stories in Latin American fintech. Recent results show 50% revenue growth, a profitable earnings inflection and accelerating monetization per user. With Mexico now open and strong early traction in Colombia, the stock looks well positioned for further multiple expansion. This trade idea lays …
Array Technologies is at an inflection: a new 60-degree DuraTrack variant and solid free cash flow position give the company room to win larger, weather-hardened utility projects in 2027. At a sub-$800M market cap and FCF of $134.7M, the risk/reward looks favorable for a long trade into mid-2027, provided developers lean into hail-resistant tracker…
Marvell's stock is pricing in a transformational customer win. Valuation still looks rich on traditional metrics, but immediate revenue and scale levers — plus a clean balance sheet and bullish technicals — create a favorable risk/reward for a mid-term swing trade. Entry, stop and targets provided.
Enbridge (ENB) offers a 5.4%+ yield, a CA$41 billion secured capital backlog through 2033 and a cash-flow profile that's largely protected by regulated and contract-backed businesses. The stock is trading below several moving averages with RSI ~30, presenting a mid-term buying opportunity. This trade idea lays out an actionable entry, stop and targ…
Tesla shares are down materially from last year's highs, but several underappreciated operational developments and compressed expectations create a defined-risk entry. This trade targets a rebound into the low $400s over the next 45 trading days, with a stop below key technical support and clear exit criteria if robotaxi delays or margin deteriorat…
Carl Zeiss Meditec (CZMWY) has bounced off its March low and technicals now show sustained bullish momentum. With a $3.36B market cap, improving moving averages, and tailwinds in ophthalmics and advanced optics, this trade aims to capture a re-acceleration over the next 45 trading days. Entry, stop and target are defined with a clearly articulated …
